Citations

Clear

16280 citation(s) found for "Yu, David".

Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1
Gutmann, David H. , James, C. David , Pöyhönen, Minna , Louis, David N. , Ferner, Rosalie E. , Guha, A. , Hariharan, S., Viskochil, David , Perry, Arie

Mayo Clinic

Neurology | May 13, 2012 | Volume: 61 | Issue: 10 | Pages: 1397-1400

10.1212/wnl.61.10.1397 | PMID 14638962 Get It

Practice parameter: Diagnosis of dementia (an evidence-based review)
DeKosky, Steven T. , Chui, Helena C. , Corey‐Bloom, Jody , Relkin, Norman , Small, Gary W. , Stevens, J E , Knopman, David S. , Cummings, Jeffrey L. , Miller, Bruce L.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 56 | Issue: 9 | Pages: 1143-1153

10.1212/wnl.56.9.1143 | PMID 11342678 Get It

Population-based study of the incidence of sudden unexplained death in epilepsy
Ficker, David M. , So, E. L., Shen, Weilun, Annegers, J. F., O’Brien, Peter C. , Cascino, Gregory D. , BELAU, PAUL G.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 51 | Issue: 5 | Pages: 1270-1274

10.1212/wnl.51.5.1270 | PMID 9818844 Get It

A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma
Kaufman, David K., Kimmel, David W., Parisi, Joseph E. , Michels, Virginia V.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 43 | Issue: 9 | Pages: 1728-1728

10.1212/wnl.43.9.1728 | PMID 8414022 Get It

A Collaborative Of Leading Health Systems Finds Wide Variations In Total Knee Replacement Delivery And Takes Steps To Improve Value
Tomek, Ivan M., Sabel, Allison L., Froimson, Mark I. , Jevsevar, David S. , Koenig, Karl , Lewallen, David G. , Naessens, James M. , Savitz, Lucy A., Westrich, James L., Weinstein, James N. , Muschler, George F. , Weeks, William Brinson

Mayo Clinic

Health Affairs | May 10, 2012 | Volume: 31 | Issue: 6 | Pages: 1329-1338

10.1377/hlthaff.2011.0935 | PMID 22571844 Get It

Dialysis Access Flow Phenomenon Demonstrated via  an Internal Jugular Central Venous Catheter Uniquely Positioned within a Superior Vena Cava Stenosis
Rosenfeld, David M. , Poterack, Karl A. , Money, Samuel R., Katariya, Nitin , Trentman, Terrence L. , Katariya, Nitin N

Mayo Clinic

Anesthesiology | May 8, 2012 | Volume: 117 | Issue: 1 | Pages: 212-215

10.1097/aln.0b013e3182592187 | PMID 22569134 Get It

Added Value of a Serum Proteomic Signature in the Diagnostic Evaluation of Lung Nodules
Pecot, Chad V. , Li, Ming , Zhang, Xueqiong J., Rajanbabu, Rama, Calitri, Ciara, Bungum, Aaron O., Jett, James R., Putnam, Joe B. , Callaway‐Lane, Carol , Deppen, Steve, Grogan, Eric L. , Worrell, John A., Shyr, Yu , Massion, Pierre P. , Carbone, David Paul , Moons, Karel G.M.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 7, 2012 | Volume: 21 | Issue: 5 | Pages: 786-792

10.1158/1055-9965.epi-11-0932 | PMID 22374995 Get It

Abstract Background: Current management of lung nodules is complicated by nontherapeutic resections and missed chances for cure. We hypothesized that a serum proteomic signature may add diagnostic information beyond that provided by combined clinical and radiographic data. Methods: Cohort A included 265 and cohort B 114 patients. Using multivariable logistic regression analysis we calculated the area under the receiver operating characteristic curve (AUC) and quantified the added value of a previously described serum proteomic signature beyond clinical and radiographic risk factors for predicting lung cancer using the integration discrimination improvement (IDI) index. Results: The average computed tomography (CT) measured nodule size in cohorts A and B was 37.83 versus 23.15 mm among patients with lung cancer and 15.82 versus 17.18 mm among those without, respectively. In cohort A, the AUC increased from 0.68 to 0.86 after adding chest CT imaging variables to the clinical results, but the proteomic signature did not provide meaningful added value. In contrast, in cohort B, the AUC improved from 0.46 with clinical data alone to 0.61 when combined with chest CT imaging data and to 0.69 after adding the proteomic signature (IDI of 20% P = 0.0003). In addition, in a subgroup of 100 nodules between 5 and 20 mm in diameter, the proteomic signature added value with an IDI of 15% (P ≤ 0.0001). Conclusions: The results show that this serum proteomic biomarker signature may add value to the clinical and chest CT evaluation of indeterminate lung nodules. Impact: This study suggests a possible role of a blood biomarker in the evaluation of indeterminate lung nodules. Cancer Epidemiol Biomarkers Prev; 21(5); 786–92. ©2012 AACR.
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Vij, Ravi , Wang, Michael , Stewart, A. Keith, Kukreti, Vishal , McDonagh, Kevin T., Alsina, Melissa , Reu, Frederic J. , Gabrail, Nashat , Belch, Andrew R. , Matous, Jeffrey, Lee, Peter P. , Rosen, Peter J., Sébag, Michaël , Vesole, David H., Kunkel, Lori, Wear, Sandra, Orlowski, Robert Z. , Kaufman, Jonathan L. , Lonial, Sagar , Jakubowiak, Andrzej , Jagannath, Sundar , Bahlis, Nizar Jacques , Wong, Alvin , Orlowski, Robert Z. , Siegel, David S. , Reu, Frederic J

Mayo Clinic

Blood | May 4, 2012 | Volume: 119 | Issue: 24 | Pages: 5661-5670

10.1182/blood-2012-03-414359 | PMID 22555973 Get It

Abstract Carfilzomib is a selective proteasome inhibitor that binds irreversibly to its target. In phase 1 studies, carfilzomib elicited promising responses and an acceptable toxicity profile in patients with relapsed and/or refractory multiple myeloma (R/R MM). In the present phase 2, multicenter, open-label study, 129 bortezomib-naive patients with R/R MM (median of 2 prior therapies) were separated into Cohort 1, scheduled to receive intravenous carfilzomib 20 mg/m2 for all treatment cycles, and Cohort 2, scheduled to receive 20 mg/m2 for cycle 1 and then 27 mg/m2 for all subsequent cycles. The primary end point was an overall response rate (≥ partial response) of 42.4% in Cohort 1 and 52.2% in Cohort 2. The clinical benefit response (overall response rate + minimal response) was 59.3% and 64.2% in Cohorts 1 and 2, respectively. Median duration of response was 13.1 months and not reached, and median time to progression was 8.3 months and not reached, respectively. The most common treatment-emergent adverse events were fatigue (62.0%) and nausea (48.8%). Single-agent carfilzomib elicited a low incidence of peripheral neuropathy—17.1% overall (1 grade 3; no grade 4)—in these pretreated bortezomib-naive patients. The results of the present study support the use of carfilzomib in R/R MM patients. This trial is registered at www.clinicaltrials.gov as NCT00530816.